Steven E. Coutre
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Steven E. Coutre sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Steven E. Coutre: 7 sponsored US clinical trials, none currently recruiting.
Steven E. Coutre sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Refractory Small Lymphocytic Lymphoma, with 1 trials.
Upper-quartile sponsor footprint
Steven E. Coutre sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
NCT03045328
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02635074
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02030405
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
NCT01550224
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
NCT00313079
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
NCT00230282
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
NCT00230334
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
How the Steven E. Coutre early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 4 completed (57%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Refractory Small Lymphocytic Lymphoma (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Steven E. Coutre: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Steven E. Coutre sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Steven E. Coutre page
7 registered trials is a research-attention snapshot, not an endorsement of Steven E. Coutre or any single study.
- None of Steven E. Coutre's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Refractory Small Lymphocytic Lymphoma is the condition Steven E. Coutre studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Refractory Small Lymphocytic Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Steven E. Coutre pipeline card: 7 registered trials from official public datasets.Report a data error.